Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza - 2Mojtaba Khamenei unconscious in Qom, not actually running Iran
- 3African nations push to recognize crimes of colonialism in Algeria
- 4Violence 'never part' of break-in plan, court told
- 5Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- 4 injured in shooting at North Carolina tree lighting ceremony
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Passenger Missing After Going Overboard Disney Cruise Ship
- How the Iran war may affect your money and bills
- Vote In favor of Your Favored Occasion Arranging Administration
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- Flu season is just beginning, but doctors are already on high alert
- Instructions to Augment the Presentation of Your Kona SUV
